Clinical trials: Time Management
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Erectile Dysfunction
Assessment of Duration of Erection With Vardenafil 10 mg
This study assessed the effect of 10mg vardenafil, taken on demand in an 'at home' setting, as compared to placebo (dummy medication with no pharmacological activity), on the duration of erection from the moment when the patient…
- Trial name
- NCT00663728
- Testing
- Levitra (Vardenafil, BAY38-9456)
- Volunteers
- 201 people
- Sponsor
- Bayer
Diabetes Mellitus, Type 1
Diabetes Technology Study of Real-Time Glucose Alerts in the Team Management of Diabetes
Many people with diabetes have a desire to share blood glucose data with other members of their team. Using a unique wireless glucose meter device, real-time wireless alerts may be automatically sent to a specific team of…
- Trial name
- NCT00322478
- Testing
- Automated informatics driven education and social networking, Blood Glucose Notifications to Remote Caregivers, Frequency of Pattern Management
- Where
- United States
- Volunteers
- 432 people
- Sponsor
- Diabetech
Osteoarthritis of the Knee
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
The objectives of this study were to characterize the local extent and duration of exposure of TA from FX006 and TCA IR, characterize the systemic PK of FX006 and TCA IR, and assess the safety and general tolerability of a single…
- Trial name
- NCT02637323
- Testing
- FX006 32 mg, TCA IR 40
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Respiratory Tract Infections
Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of PF-04287881 after a single oral dose in healthy adult volunteers.
- Trial name
- NCT00793000
- Testing
- PF-04287881
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Pfizer
Osteoarthritis of the Knee
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
- Trial name
- NCT02003365
- Testing
- FX006 10 mg, FX006 40 mg, TCA IR 40 mg
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Cerebrovascular Accident
Anti-MAG First Administration to Human
GSK249320 is a monoclonal antibody directed against myelin associated glycoprotein (MAG), a protein that inhibits axonal regeneration.
- Trial name
- NCT00622609
- Testing
- GSK249320A
- Where
- 2 sites in United States, Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers
Safety, tolerability and pharmacokinetics of BIII 890
- Trial name
- NCT02269215
- Testing
- BIII 890 CL
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Lymphedema
Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema
The objective of the study is to assess the effect of a new Armsleeve, worn during the night during maintenance phase of upper limb lymphoedema treatment in combination with Day-time usual lymphology hosiery.
- Trial name
- MARILYN (NCT02253186)
- Testing
- Auto-Adjustable MOBIDERM Armsleeve
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Thuasne
Healthy
Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers
The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIIR 561 after continuous intravenous administration of increasing doses in healthy young volunteers
- Trial name
- NCT02222961
- Testing
- BIIR 561 CL
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Endometriosis
A Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy, Safety and Duration of Effect of a Single Administration of Various Doses of Cetrorelix SR in Subjects With Histologically Confirmed Endometriosis
Identify effective doses of cetrorelix SR in the treatment of symptoms of endometriosis, describe dose effect relationship and duration of symptom relief
- Trial name
- NCT00244452
- Testing
- Cetrorelix
- Where
- 57 sites in Australia, Belgium and 6 more
- Sponsor
- Solvay Pharmaceuticals
Healthy
Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL
The objective of the study is to obtain information about safety, tolerability and pharmacokinetics of BIIR 561 CL after single intravenous administration of increasing doses in healthy male volunteers
- Trial name
- NCT02222974
- Testing
- BIIR 561 CL
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Healthy
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin
Normal subjects will receive unfractionated heparin followed by a single dose of PER977 with dose escalation by cohort. Ten subjects enrolled in Cohort 4 will receive a single dose of PER977 followed by a one-week washout and…
- Trial name
- NCT02206087
- Testing
- PER977, Heparin Sodium
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Peripheral Artery Disease (PAD)
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have…
- Trial name
- TI-PAD EVR (NCT02227368)
- Testing
- Ticagrelor, Comparator
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Fungus Diseases
PROPHESSOR: AmBisome in Antifungal Primary Prophylaxis Treatment of High Risk Patients Undergoing Allogeneic Stem Cell Transplantation
This pilot study was designed in order to evaluate the safety and efficacy of an AmBisome® loading dose regimen, in a weekly administration schedule during the initial phase of allogeneic stem-cell transplant and in case of…
- Trial name
- NCT00326157
- Testing
- AmBisome
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Gilead Sciences
Renal Failure, Chronic Kidney Disease
Clinical Performance of the Therapy Option FlexPoint of the PD Cycler Sleep•Safe Harmony
Analysis and comparison of treatments with and without the FlexPoint technology (flexible volume and dwell time management) of the PD cycler sleep•safe harmony
- Trial name
- FlexPoint (NCT06390592)
- Testing
- PD cycler
- Volunteers
- 24 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Prostate Cancer
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence
- Trial name
- NCT07569926
- Testing
- fluciclovine (18F)
- Where
- 6 sites in United States
- Volunteers
- 142 people
- Sponsor
- Blue Earth Diagnostics
Healthy
Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers
Investigate the bioavailability of BI 1356 BS and of metformin after concomitant multiple oral administration of 10 mg BI 1356 BS tablets and 3 x 850 mg metformin in comparison to BI 1356 BS and metformin given alone
- Trial name
- NCT02183506
- Testing
- Metformin, BI 1356 BS
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Metabolic Disorders, Non-alcoholic Steatohepatitis
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in…
- Trial name
- NCT04142424
- Testing
- AZD2693
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca